Advertisement
Advertisement

OMER

OMER logo

Omeros Corporation

13.62
USD
Sponsored
+0.37
+2.79%
Aug 10, 16:00 UTC -4
Closed
exchange

After-Market

13.53

-0.09
-0.70%

Omeros Corporation Profile

About

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

Info & Links

CEO

Gregory A. Demopulos

Headquarters

201 ELLIOT AVENUE WEST
SEATTLE, WA 98119, UNITED STATES

Industry

Medical Products

Sector

Medical

Website

www.omeros.com

Auditor

Ernst & Young LLP

Share holders

76

Employees

175

Omeros Corporation Statistics

Valuation Measures

Market Capitalization2

978.88M

Enterprise Value

1.11B

Enterprise Value/EBITDA(ttm)

-10.61

Price to Earnings Ratio(ttm)

6.08

Price to Sales(ttm)

--

Price to Book(mrq)

--

Price to Cash(ytd)

7.08

Profitability

Gross Margin(ttm)

23.52%

Operating Margin(ttm)

--

Profit Margin(ttm)

141.67%

Return on Equity(ttm)

-102.16%

Return on Invested Capital(ttm)

229.34%

Return on Assets(ttm)

64.87%

Income Statement

Revenue(ttm)

9.89M

Revenue Per Share(ttm)

0.14

Gross Profit(ttm)

9.31M

EBITDA(ttm)3

-104.98M

Net Income Available to Common(ttm)

86.17M

Diluted EPS(ttm)

0.70

Share Statistics

Beta (5Y Monthly)

2.54

52-Week Change

235.47%

S&P 500 52-Week Change

21.65%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

72.38M

Dividend Yield

0.00%

Float4

64.78M

% Held by Insiders

10.50%

% Held by Institutions

48.79%

Balance Sheet

Total Cash(mrq)

135.32M

Total Cash Per Share(mrq)

1.87

Total Debt(mrq)

136.84M

Total Debt/Equity(mrq)

-216.05%

Current Ratio(mrq)

3.03%

Quick Ratio(mrq)

3.03%

Book Value Per Share(mrq)

-0.88

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.16

Free Cash Flow(ytd)

-14.51M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement